97 results
6-K
RDHL
Redhill Biopharma Ltd.
24 Apr 24
Current report (foreign)
7:05am
being evaluated in the early treatment arm of the study. The primary efficacy assessment in the early treatment indication will be time to sustained
POS AM
RDHL
Redhill Biopharma Ltd.
18 Apr 24
Prospectus update (post-effective amendment)
7:00am
and Boone, LLP.
EXPERTS
The financial statements and management's assessment of the effectiveness of internal control over financial reporting
424B5
RDHL
Redhill Biopharma Ltd.
2 Apr 24
Prospectus supplement for primary offering
4:05pm
by Haynes and Boone, LLP.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over financial … upon for us by Haynes and Boone, LLP.
EXPERTS
The financial statements and management’s assessment of the effectiveness of internal control over
6-K
RDHL
Redhill Biopharma Ltd.
5 Mar 24
Current report (foreign)
7:01am
as a potential medical countermeasure (MCM) against inhalation Sulfur Mustard exposure. The overall evaluation will also include assessment of opaganib’s
424B5
ctti 5e6o8ykwqo
26 Jan 24
Prospectus supplement for primary offering
9:29am
6-K
unlmyxz234
4 Dec 23
Current report (foreign)
7:03am
424B3
s015rd 98e
26 Oct 23
Prospectus supplement
4:52pm
F-3/A
kam n6u66c9ij626g52c
23 Oct 23
Shelf registration (foreign) (amended)
4:06pm
F-3
jofzdo8chlfgo 1wt8x
13 Oct 23
Shelf registration (foreign)
8:13am
424B3
zqcswegr03bq9ff
11 Aug 23
Prospectus supplement
4:52pm
F-3
si4o1f0nekfxb5zxfo0d
4 Aug 23
Shelf registration (foreign)
4:05pm
6-K
lkrg8z h2cazxfke3
31 Jul 23
Current report (foreign)
7:03am
424B5
76sedt124q6k
25 Jul 23
Prospectus supplement for primary offering
8:00am
424B5
7hd6oe9vd
3 Apr 23
Prospectus supplement for primary offering
8:49am
424B5
f1ja9wmrrsca
6 Dec 22
Prospectus supplement for primary offering
6:04am
6-K
EX-1.1
rkz qxfpv
5 Dec 22
Current report (foreign)
4:24pm
424B5
votpu1 bk3erv
2 Dec 22
Prospectus supplement for primary offering
6:31am